Weight Loss Telemedicine - Dr. Moe

Weight Loss Telemedicine operates as a telehealth-focused practice in Carmel, Indiana, providing medically supervised weight management programs under the direction of Dr. Moe. The clinic specializes in prescribing and monitoring GLP-1 receptor agonist peptides for patients seeking structured weight reduction without the need for in-person office visits. By operating exclusively through virtual consultations, the practice serves patients throughout Indiana who prefer the convenience of remote medical care while accessing prescription weight loss therapies that require physician oversight and ongoing metabolic monitoring.

The clinic's treatment protocol centers on two FDA-approved GLP-1 medications: liraglutide and semaglutide. Liraglutide, administered as a daily subcutaneous injection, works by mimicking the incretin hormone GLP-1 to regulate appetite and slow gastric emptying, typically prescribed for patients with a BMI of 30 or higher, or 27 with weight-related comorbidities. Semaglutide, available as a weekly injection, operates through the same mechanism but with extended duration of action, allowing for less frequent dosing while producing comparable effects on satiety signaling and glucose metabolism. Dr. Moe evaluates each patient's medical history, current medications, and weight loss goals to determine appropriate peptide selection, starting dosages, and titration schedules based on individual tolerance and response patterns. The practice does not offer compounded versions of these medications, focusing instead on FDA-approved formulations with established safety profiles and consistent manufacturing standards.

Dr. Moe conducts all initial consultations and follow-up appointments via HIPAA-compliant video conferencing, reviewing lab work, vital signs, and patient-reported outcomes to adjust treatment plans as needed. Patients typically begin with comprehensive metabolic panels and thyroid function tests to rule out contraindications before starting GLP-1 therapy. The clinic requires regular check-ins during the titration phase—usually every two to four weeks—to monitor for common side effects including nausea, constipation, and injection site reactions, as well as to track weight loss progress and make dose adjustments. Dr. Moe provides specific guidance on injection technique, medication storage, and strategies for managing gastrointestinal symptoms that often accompany the initial weeks of GLP-1 therapy. The practice emphasizes that these medications function as tools within a broader lifestyle modification framework rather than standalone solutions, though the clinic's primary focus remains pharmacological intervention rather than comprehensive nutrition counseling or exercise programming.

Patients scheduling with Weight Loss Telemedicine in Carmel can expect a streamlined intake process conducted entirely online, with prescription fulfillment coordinated through partner pharmacies that ship directly to the patient's home or offer local pickup options. The clinic maintains a concierge-style approach with relatively quick appointment availability and direct communication channels to Dr. Moe's office for questions between scheduled visits. Most patients remain on GLP-1 therapy for a minimum of several months, with some continuing for a year or longer depending on weight loss goals and metabolic response. The practice does not accept insurance for telehealth weight loss consultations, operating on a cash-pay model with transparent pricing for consultation fees separate from medication costs, which vary based on insurance coverage and pharmacy pricing for the prescribed peptide.

The clinic's telehealth-exclusive model eliminates geographic barriers for Indiana residents who lack access to local providers experienced in GLP-1 weight management or who prefer the privacy and convenience of virtual care. Weight Loss Telemedicine does not provide surgical weight loss consultations, hormone replacement therapy, or treatment for eating disorders, maintaining a focused scope of practice around peptide-based pharmacotherapy for obesity and overweight conditions. Dr. Moe's approach prioritizes patient education about realistic weight loss expectations, potential side effects, and the importance of maintaining results after medication discontinuation, acknowledging that GLP-1 therapies often require long-term or indefinite use to sustain weight reduction in many patients.